8-K Announcements
6Material company update
Feb 23, 2026·SEC
Material company update
Jan 16, 2026·SEC
Material company update
Jan 16, 2026·SEC
Sharps Technology, Inc.(STSS)Earnings, Financials & Key Ratios
STSS•NASDAQ
$1.11
Price updated Jul 7, 2026
AboutSharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.Show more
- Revenue$204K
- EBITDA-$13M-85.8%
- Net Income-$283M-2938.9%
- EPS (Diluted)-11.16+99.5%
- Gross Margin-202.49%
- EBITDA Margin-6447.16%
- Operating Margin-6512.09%
- Net Margin-138400.02%
- ROE-212.11%-13.3%
STSS Price & Volume
Sharps Technology, Inc. (STSS) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Deficits Threaten Commercial Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital exhaustion and dilution
Key Thesis Takeaways
- Sharps Technology remains in a precarious pilot phase, characterized by a TTM revenue of only $204,120 and a structural inability to achieve unit-level profitability against established medical device incumbents.
- The company's reliance on external financing is underscored by a massive accumulated deficit of -$403.2 million, which continues to erode shareholder equity.
- Investors should monitor the firm's ability to scale production, as the current cost structure and persistent negative free cash flow suggest a high risk of total capital exhaustion.
Verdict Logic
the company's fundamental outlook is constrained by a persistent negative net margin of -447.3% and a lack of meaningful revenue growth to offset its ongoing operational cash burn.
STSS Growth Metrics
Sharps Technology, Inc. (STSS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-5705.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.5%
Return on Capital
10 Years-160.38%
5 Years-116.43%
3 Years-92.21%
Last Year-9.98%
Peers Comparison
Key metrics vs top competitors for Sharps Technology, Inc. (STSS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.11 | $46.98M | -0.10 | — | -138400.02% | -212.11% | — | |
| $3.49 | $184.18M | -3.26 | -9.06% | -8.03% | -22.93% | — | |
| $72.14 | $4.3B | 33.87 | 11.66% | 9.03% | 8.95% | — | |
| $28.94 | $734.45M | -22.97 | -3.24% | -12.67% | -10.13% | — | |
| $3.09 | $50.87M | -6.57 | -34.26% | -34.5% | -15.79% | — | |
| $156.30 | $56.63B | 26.81 | 8.23% | 5.33% | 4.54% | — |
Compare STSS vs Peers
Sharps Technology, Inc. (STSS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STSS SEC Filings & Documents
Sharps Technology, Inc. (STSS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when STSS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STSS Frequently Asked Questions
Sharps Technology, Inc. (STSS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Sharps Technology, Inc.'s revenue?
Sharps Technology, Inc. (STSS) reported $0.4M in revenue for fiscal year 2025.
Is STSS profitable?
Sharps Technology, Inc. (STSS) reported a net loss of $370.7M for fiscal year 2025.
Dividend & Returns
What is STSS's return on equity?
Sharps Technology, Inc. (STSS) has a return on equity (ROE) of -212.1%. Negative ROE indicates the company is unprofitable.
What is Sharps Technology, Inc.'s free cash flow?
Sharps Technology, Inc. (STSS) had negative free cash flow of $203.0M in fiscal year 2025, likely due to heavy capital investments.